SequelSEC

INSMED Inc INSM

Pharmaceutical Preparations · CIK 0001104506 · Fiscal year ends 1231

Revenue
$1.52B
Fiscal year ended 2026-09-30
Operating income
-$563.98M
Fiscal year ended 2026-09-30
Free cash flow
-$627.58M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$21.10BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$97.89Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue34.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity28.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth66.7%80th
CapEx / revenue5.4%68th
Gross margin79.7%67th
Long-term debt / equity0.73x63th
FCF margin-159.6%43th
R&D / revenue127.2%45th
Net margin-210.5%47th
SBC / revenue25.2%51th
Operating margin-205.6%51th
Current ratio3.83x51th

INSMED Inc (INSM) reported revenue of $1.52B and net income of -$605.61M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from INSMED Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

INSMED Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$1.52B
Cost of revenue$237.07M
Gross profit$1.28B
Operating income-$563.98M
Net income-$605.61M
Research & development$944.39M
Weighted-average diluted sharesUnavailable
Pretax income-$598.06M
Income tax expense$7.55M
Diluted EPSUnavailable
Selling, general & administrative$960.24M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

INSMED Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$396.56M
Total assets$2.23B
Current assets$1.71B
Total liabilities$1.50B
Current liabilities$596.58M
Total equity incl. NCI$726.21M
Temporary (mezzanine) equityUnavailable
Inventory$163.95M
Accounts receivable$259.27M
Goodwill$136.11M
Long-term debt$544.86M
Accounts payable$84.30M

Cash flow

INSMED Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$595.62M
Capital expenditures$31.95M
Investing cash flow$543.80M
Financing cash flow$114.19M
Net change in cash$61.80M
Stock-based compensation$167.27M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

INSMED Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$627.58M
Gross margin84.4%
Operating margin-37.1%
FCF margin-41.3%
SBC / revenue11.0%
Current ratio2.86x
Revenue YoY growth240.0%
Net margin-39.9%
R&D / revenue62.1%
CapEx / revenue2.1%
Long-term debt / equity0.75x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INSM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.